{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-26-009081","form_type":"8-K","ticker":"CRVO","cik":"0001053691","company_name":"CervoMed Inc.","filed_at":"2026-03-19T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.474132+00:00","generated_at":"2026-05-15T09:34:18.878161+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"CervoMed Phase 2b DLB data show greater benefit in patients without AD co-pathology","bullets":["At pTau181 <21 pg/mL, neflamapimod showed CDR-SB improvement of -1.11 vs placebo (p=0.005) in within-participant analysis.","PK/PD analyses identified therapeutic trough concentration threshold of 4 ng/mL; DP Batch B achieved this in 75% of patients vs 50% for Batch A.","Planned Phase 3 trial will use pTau181 <21 pg/mL enrichment, expecting 80-90% of patients without AD co-pathology.","Data presented March 21, 2026 at AD/PD 2026 Conference in Copenhagen, Denmark."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-009081","json":"https://secwatch.observer/filing/0001437749-26-009081.json","markdown":"https://secwatch.observer/filing/0001437749-26-009081.md","text":"https://secwatch.observer/filing/0001437749-26-009081.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1053691/000143774926009081/0001437749-26-009081-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1053691/000143774926009081/crvo20260319_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T09:34:18.878161+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}